Drug intelligence / Profile preview

5-fluorouracil + cyclophosphamide + doxorubicin + prednisone + tamoxifen + vincristine

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a multi-drug chemotherapy and hormonal therapy combination regimen used primarily for the treatment of breast cancer. The regimen combines cytotoxic agents (5-fluorouracil, cyclophosphamide, doxorubicin, vincristine) with a corticosteroid (prednisone) and an estrogen receptor modulator (tamoxifen). This combination has been studied in clinical trials for both adjuvant therapy and treatment of advanced/metastatic breast cancer.

Targets

ER (Estrogen receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on 5-fluorouracil + cyclophosphamide + doxorubicin + prednisone + tamoxifen + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + cyclophosphamide + doxorubicin + prednisone + tamoxifen + vincristine.

Explore the full profile